AstraZeneca reports latest positive results from Imfinzi trials

by | Oct 15, 2021

AstraZeneca said on Friday that positive high-level results from the ‘HIMALAYA’ phase 3 trial showed a single, high priming dose of tremelimumab added to ‘Imfinzi’, or durvalumab. demonstrated a statistically-significant and clinically meaningful overall survival (OS) benefit.
The FTSE 100 drugmaker said the results, versus sorafenib, tested the regime as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy, and were not eligible for localised treatment.

It said the novel dose and schedule of tremelimumab, an anti-CTLA4 antibody, and Imfinzi was dubbed the ‘STRIDE’ regimen, or ‘Single Tremelimumab Regular Interval Durvalumab’.

The combination demonstrated a favourable safety profile, and the addition of tremelimumab to Imfinzi did not increase severe hepatic toxicity.

Imfinzi alone demonstrated non-inferior overall survival to sorafenib, with a numerical trend in favour of Imfinzi and an improved tolerability profile compared to sorafenib.

Liver cancer, of which HCC is the most common type, is the third leading cause of cancer death and the sixth most commonly diagnosed cancer worldwide with approximately 900,000 people diagnosed each year.

Just 7% of patients with advanced disease survive five years.

“Inhibition of CTLA-4 has shown the ability to drive benefit particularly in the tail of the survival curve in several settings,” said executive vice-president of oncology research and development, Susan Galbraith.

“This is the first time a dual immunotherapy regimen has improved overall survival as a 1st-line treatment for patients with unresectable liver cancer for whom treatment options are limited and long-term outcomes are poor.”

At 0908 BST, shares in AstraZeneca were down 0.31% at 8,787p.

Related articles

Ryanair passenger numbers jump 9% in December

Ryanair passenger numbers jump 9% in December

(Sharecast News) - Budget airline Ryanair reported a 9% jump in December passenger numbers on Wednesday. Traffic rose to 12.54 million from 11.52m in the same month a year earlier, while the load factor - which gauges how full the planes are - ticked down to 91% from...

Wizz Are passenger numbers soar in December

Wizz Are passenger numbers soar in December

(Sharecast News) - Hungary-based budget airline Wizz Air reported a strong rise in December passenger numbers as demand continued to rebound from the Covid pandemic. The company on Wednesday said it carried 4,964,857 passengers, an 18.8% increase year on year. For the...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x